288 related articles for article (PubMed ID: 24154825)
1. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
Chen LC; Chen TC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
[TBL] [Abstract][Full Text] [Related]
2. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan.
Chen TC; Chen LC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):172-81. PubMed ID: 24242992
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
[TBL] [Abstract][Full Text] [Related]
4. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
[TBL] [Abstract][Full Text] [Related]
5. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
[TBL] [Abstract][Full Text] [Related]
7. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
8. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Efficace F; Baccarani M; Rosti G; Cottone F; Castagnetti F; Breccia M; Alimena G; Iurlo A; Rossi AR; Pardini S; Gherlinzoni F; Salvucci M; Tiribelli M; Vignetti M; Mandelli F
Br J Cancer; 2012 Sep; 107(6):904-9. PubMed ID: 22871884
[TBL] [Abstract][Full Text] [Related]
9. Cultural factors related to adherence to imatinib in CML: a Mexican perspective.
Cantú-Rodríguez OG; Sánchez-Cárdenas M; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Mancias-Guerra C; González-Llano O; Gómez-Almaguer D
Hematology; 2015 Mar; 20(2):72-6. PubMed ID: 25034734
[TBL] [Abstract][Full Text] [Related]
10. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
[TBL] [Abstract][Full Text] [Related]
11. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
12. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
13. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
14. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
Jönsson S; Olsson B; Söderberg J; Wadenvik H
Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
Noens L; van Lierde MA; De Bock R; Verhoef G; Zachée P; Berneman Z; Martiat P; Mineur P; Van Eygen K; MacDonald K; De Geest S; Albrecht T; Abraham I
Blood; 2009 May; 113(22):5401-11. PubMed ID: 19349618
[TBL] [Abstract][Full Text] [Related]
16. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
18. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; Desai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS
J Clin Oncol; 2010 May; 28(14):2381-8. PubMed ID: 20385986
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-induced Stevens-Johnsons syndrome.
Jha P; Himanshu D; Jain N; Singh AK
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
